Vaccination clearly reduces both symptomatic and severe COVID-19. Understanding which immune mechanisms mediate protection against severe outcomes is crucial for next-generation vaccine design. While neutralising antibodies are established correlates of protection against acquisition of COVID-19, their role in preventing progression from infection to severe disease remains less well defined. The authors framed the specific question as whether higher vaccine-induced neutralisation titres are associated with lower risk of progression to severe COVID-19 among people who become infected despite vaccination.
The study combined two evidence streams. First, a systematic search identified 25 published clinical studies reporting vaccine effectiveness or relative risks for progression from SARS-CoV-2 infection to severe COVID-19 (hospital or ICU admission). Second, the authors used neutralisation titre data drawn from 301 post-vaccination studies compiled in the Stanford University Coronavirus antiviral and resistance database. Clinical study estimates and neutralisation GMTs from vaccine/variant combinations were matched and analysed using a meta-regression framework.
Matched clinical protection estimates were modelled against the corresponding vaccine-induced geometric mean neutralisation titres (GMTs). The principal outcome was the association between neutralisation level (on a log scale) and the relative risk (RR) of progression to severe COVID-19 among infected individuals. The authors used meta-regression to synthesise across studies and vaccine-variant contexts. They explicitly note that neutralisation measurements and clinical outcome data were derived from different studies and that this cross-study matching is a key methodological consideration.
Across the assembled datasets, higher post-vaccination neutralisation titres were associated with reduced risk of progression to severe COVID-19. Quantitatively, the meta-regression estimated a relative risk of 0.57 per 10-fold increase in GMT (95% CI 0.51–0.64, p < 0.001). This indicates that, after infection, individuals whose vaccination elicited higher neutralising titres were significantly less likely to progress to hospital or ICU-level disease compared with those with lower titres. The synthesis supports the interpretation that vaccine-induced neutralising antibodies are correlated with protection from progression to severe outcomes and can account for at least a partial mechanistic role.
The authors compared the magnitude of protection against progression achieved by vaccination to that afforded by therapeutic passive administration of antibodies given to infected, unvaccinated patients. They found that vaccine-associated protection from progression was higher than protection provided by passive antibody treatments used therapeutically after infection. The observed difference suggests that antibody quantity alone may not fully explain vaccine protection and that timing and/or other immune functions likely contribute.
The principal methodological limitations are clearly stated:
Neutralisation titres and clinical outcome measures were not obtained from the same individuals; the analysis relied on matching across separate study bodies. This cross-study matching can leave residual confounding unaccounted for if study populations or measurement contexts differ.
There is potential for unmeasured confounding in the clinical protection estimates and in mapping titres to those estimates across different vaccine platforms and variants.
The study design and available data do not permit definitive causal attribution; correlations between neutralising antibody levels and protection do not prove that neutralising antibodies are solely responsible for protection from progression.
This meta-analysis provides evidence that higher vaccine-induced neutralising antibody titres correlate with reduced risk of progression to severe COVID-19 following breakthrough infection. The findings imply that neutralising antibodies can mediate at least part of the protection against severe outcomes provided by vaccination. However, because vaccine protection from progression exceeded that observed with therapeutic passive antibodies, other immune responses — for example T cell responses or nonneutralising antibody functions — and the timing of antibody presence during infection are likely important contributors to the remaining protection gap. These insights underscore the importance of considering multiple arms of the immune response in vaccine design and evaluation, particularly for vaccines aimed at preventing severe disease in vulnerable populations.
The authors report that code and data supporting the analysis are publicly available via a Zenodo DOI cited in the article. The work was supported by Australian funding bodies including National Health and Medical Research Council investigator grants and an Australian Government Research Training Program scholarship. The authors declared no competing interests.
This summary is based on Elias KM et al., "Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis," PLoS Medicine, published September 2, 2026. Full article, data, and code are available from the published paper and associated Zenodo repository as cited by the authors.